A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors

This Study is
No Longer Enrolling

Details
Age

Adult

Eligibility

patients must have germline or somatic mutation in DDR genes, actionable mutation in PTEN gene or hotspot mutation in the PIK3CA gene

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 19-1987

More information available at ClinicalTrials.gov: NCT03842228

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers